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ABSTRACT
The effects of nicotine administration on structural and cellular parameters of bone 
histomorphometry, cotinine, and biomarkers of bone remodeling were studied in twenty-one 
Sprague-Dawley male rats.  Rats aged three months and weighing between 250-300 g were divided 
into three groups.  Group 1 was the baseline group, which was sacrificed without treatment.  The 
other  groups were the control group and the nicotine group.   The nicotine group was treated with 
nicotine 7 mg/kg body weight and the C group was treated with normal saline only.  Treatment was 
given by intraperitoneal injection, six days a week for a period of 4 months.  Histomorphometric 
analysis was done on the metaphyseal region of the trabecular bone of the left femur by using 
an image analyzer.  Biochemical analysis was done using ELISA-test kit to compare the serum 
cotinine, osteocalcin and pyridinoline (PYD) levels between pretreatment and after 4 months 
treatment in the control and nicotine groups.  Histomorphometric analysis revealed that nicotine 
significantly decreased the trabecular bone volume (BV/TV) and the osteoblast surface (Ob.S/BS), 
and increased the osteoclast surface (Oc.S/BS) and the eroded surface (ES/BS) compared to the 
baseline and control groups.  In addition, biochemical analysis showed that nicotine treatment 
for 4 months significantly decreased the osteocalcin (bone formation marker) levels while the 
cotinine and PYD (bone resorption marker) levels were increased as compared to pretreatment. 
We concluded that treatment with nicotine 7 mg/kg for 4 months exerted negative a effect on the 
trabecular bone histomorphometric parameters and bone remodeling biomarkers. 
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INTRODUCTION
Cigarette smoke contains high concentrations of oxidants and free radicals (Church & Pryor 
985, Pryor & Stone 993) and is well known as one of the exogenous factors of oxidative stress 
in human populations (Block et al., 00).  Nicotine, one of more than 4700 compounds found 
in unfiltered mainstream tobacco smoke (Hoffmann et al., 00) can stimulate angiogenesis and 
atherosclerosis, promote tumor growth (Heeshen et al., 00) and osteoporosis (Braulik & Jarab 
1993).  Approximately 85% of nicotine is rapidly transformed to the main metabolite, cotinine 
(Benowitz et al., 983).  The half-life period of cotinine is about 8 to 0 hours compared with 
only  to  hours for nicotine (Benowitz & Jacob 993).  As a consequence cotinine has become 
the principal biomarker of nicotine exposure in tobacco research paradigms (Ziegler et al., 004). 
 Animal experiments have shown that nicotine induced oxidative stress in both in vitro and 
in vivo (Wetscher et al., 994, Kalpana & Menon, 004).  Crowley-Weber and coworker (003) 
reported that nicotine increased oxidative stress, activated nuclear transcription factor-kB (NF-
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kB), induced apoptosis and increased genotoxic stress in the tissues of smokers.  NF-kB-signaling 
pathways are important for bone homeostasis, in particular for osteoclast differentiation (Jimi & 
Ghosh 2005).  Recently, oxidizing agent (Ferric nitrilotriacetate, Fe-NTA) was found to effect bone 
metabolism by suppressing bone growth and increasing bone resorbing cytokines (interleukin-, 
interleukin-6) (Ahmad et al., 004; Ahmad et al., 005). 
A number of investigations have shown that nicotine might have a direct effect on bone 
metabolism by influencing the bone remodeling process.  Nicotine suppressed cellular proliferation 
in UMR 106-01 rat osteoblastic osteosarcoma cells (Fang et al., 99) and suppressed osteogenesis 
through a decrease in alkaline phosphatase (ALPase) and type I collagen production by osteoblasts 
(Tanaka et al., 005).  In contrast, nicotine appears to stimulate osteoclasts resorption in a porcine 
marrow cell model (Henemyre et al., 003) and increased bone resorption by induction of the bone 
resorbing cytokine, interleukin- (Norazlina et al., 004).  These studies suggested that nicotine was 
not only a direct inhibitor of osteoblast differentiation but also a regulator of osteoclast activity.
 Biochemical markers of bone remodeling can be measured in the serum or urine and reflect 
the various processes involved in bone metabolism by detecting the activity of osteoblasts and 
osteoclasts (Weisman & Matkovic, 005).  Osteoblasts synthesise type I collagen, growth factors 
and non-collagenous proteins.  Osteocalcin is a bone specific non-collagenous protein which is 
widely accepted as an indicator of osteoblast activity (Risteli & Risteli, 1993) and known as a 
sensitive and specific marker of bone formation (Dogan & Posaci, 2002).  Whereas, osteoclasts 
resorb bone and collagen type I.  When collagen is degraded, pyridinolines and telopeptides are 
released into extracellular fluids and subsequently transported in to blood and urine (Watts, 1999). 
Pyridinoline (PYD) and deoxypyridinoline (DPD) are collagen crosslinks that are mainly found in 
bone and known as the most promising markers of bone resorption (Dogan & Posaci, 993).   
Bone histomorphometric analysis has been used extensively to study the morphological 
changes in cancellous bone.  This method allows the study of bone at the tissue or cell level to enable 
cellular measurements at the intermediary level of bone organization.  Besides that, biochemical 
markers of bone formation and resorption are relatively sensitive indicators of bone turnover but 
do not reflect the changes in bone mass and enable assessment of bone structure (Compston & 
Croucher, 99).  A combination of bone histomorphometry and biochemical analysis therefore 
will provide a powerful tool to assess the changes in the bone morphology and metabolism, and 
also to evaluate bone cellular activities.  
In this present study, nicotine was used to induce oxidative stress in rats and the effects on 
bone were measured with structural and cellular bone histomorphometric, and serum biochemical 
markers of bone remodeling analysis.  We hope it will provide a better understanding of the adverse 
effects of nicotine on bone turnover and the negative impact of smoking on bone health.
MATERIALS AND METHODS
Animals and treatment
Twenty-one male Sprague-Dawley rats, about 3 months old and weighing 50-300 gram 
were obtained from the Animal Unit, Faculty of Medicine, Universiti Kebangsaan Malaysia.  The 
rats were kept two and three per cage under 12 hour natural light-dark cycles.  Rats were allowed 
to acclimatize for one week before the treatment was started, and were given tap water ad libitum 
and normal rat chow obtained from Gold Coin (Port Klang, Malaysia).  The rats were randomly 
assigned into 3 groups with 7 rats in each group.  Group  was the baseline group, which was 
sacrificed without treatment.  The other 2 groups were the control group and the nicotine group. 
The nicotine group was treated with nicotine 7 mg/kg body weight and the control group was treated 
with normal saline only.  Nicotine and normal saline solutions were injected intraperitoneally. 
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The rats’ body weights were measured weekly.  Treatment period was 4 months.  This study was 




The nicotine used was nicotine hydrogen tartrate salt, which was purchased from Sigma 
(St. Louis, USA).  Nicotine at a concentration of 7 mg/kg was prepared by mixing 0.07 gram of 
nicotine in 0 ml normal saline.  A total of 0. ml/00g rat weight of the preparation was given 
intraperitoneally 6 days a week for 4 months.  
Specimen collection
For biochemical analysis (control and nicotine groups), blood samples were collected before 
the start of treatment and after 4 months of treatment.  Samples were obtained from the retro-
orbital vessel after the rat had been anesthetized with diethyl ether.  After 3 hours the blood was 
centrifuged at 1000 rpm for 10 minutes (IEC Centra-EC4R, USA) to obtain the serum and stored 
in freezer at the temperature of -70◦C.  For bone histomorphometric analysis (baseline, control 
and nicotine groups), the rats were anaesthetized with diethyl ether and sacrificed by cervical 
dislocation.  The femurs were removed and the distal parts were kept in 70% ethanol.  
Bone histomorphometry 
The distal part of the rat femur was fixed with 70% ethanol and cut into 2 fractions for 
preparing undecalcified and decalcified samples.  Undecalcified bone sample were processed and 
embedded in polymer methyl methacrylate (BDH, Poole, England) medium according to Difford 
(1974).  The polymer block was sectioned at 9 μm thickness using a microtome (Leica RM2155, 
GmbH, Germany), stained with Von Kossa for structural parameters and Masson Goldner stain 
for osteoid measurements. The decalcified samples were decalcified with EDTA for 2 months and 
embedded in paraffin. The paraffin blocks were sectioned at 5 μm thickness with a microtome 
(Leica RM2135, GmbH, Germany) and stained with hematoxylin and eosin for identification and 
measurement of osteoblasts and osteoclasts.  Nomenclature and symbols used were as described 
by the American Society of Bone Mineral Research (ASBMR) Histomorphometry Nomenclature 
Committee (Parfitt et al., 987).  
The parameters of bone histomorphometry were measured using an image analyzer.  For 
structural parameter measurements, analysis was done using VideoTest-Master software (VT, 
St.-Petersburg, Russia; LB Technology Supp. Sdn. Bhd., Kuala Lumpur, Malaysia).  For static 
parameter measurements, analysis was done using software Pro-Plus 5.0 (Media Cybernatics, 
Silver Spring, MD, USA) and Weibel technique (Weibel et al., 966, Freere & Weibel, 967). 
All analysis were done randomly at the metaphyseal region, 3 to 7 mm above the growth plate 
(Baldock et al., 998).   
Biochemical markers of bone remodeling
Serum cotinine, osteocalcin and pyridinolines (PYD) were measured before and after 
treatment using an enzyme linked immunoassay (ELISA) and enzyme immunoassay (EIA) 
techniques.  Kits used were Cotinine ELISA kit (DRG Instruments, GmbH, Germany), Rat-MID 
Osteocalcin ELISA kit (Nordic Bioscience Diagnostics A/S, Herlev, Denmark) and METRA Serum 
PYD EIA kit (Quidel Corporation, San Diego, CA, USA) and were measured using an ELISA 
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reader (VERSAmax, Sunnyvale, CA, USA).
Statistical analysis
Data analysis was performed using Statistical Package for Social Sciences (SPSS .0., 
Chicago, IL, USA) software.  Normality test used was the Kolmogorov-Smirnov test.  Statistical 
test used was ANOVA followed by Tukey’s hsd for normally distributed data and Kruskal-Wallis 
and Mann-Whitney test for data that was not normally distributed.  Comparison of data between 
before and after the treatment period for the same group was done using the paired Student’s t-test. 
To compare data from the control group and nicotine group, unpaired Student’s t-test was used. 
For all analyses, differences were considered significant at P < 0.05.  The results were presented as 
mean values ± standard error of the mean (SEM).     
RESULTS
Effects of nicotine on body weight
We observed a time-dependent gain in weight among both control and nicotine groups. 
Body weight increased steadily from week-0 to week-6.  However, in the middle phase of the 
study beginning week-7 to week-16, the nicotine group had significantly lower body weight as 
compared to the control group (Figure ).  
Figure . Mean body weight progress of control group and nicotine group (week-0 to week-6).
Control group : Normal saline 0. ml/00kg
Nicotine group : Nicotine 7 mg/kg
All values are expressed in Mean ± SEM, *P < 0.05 compared with control group
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Figure 2. Photomicrographs of trabecular bone. Undecalcified section (100x magnification) shows trabecular bone 
(black) with white background stain with Von Kossa method in baseline (A), control (B) and nicotine (C) groups.
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Bone histomorphometry 
After 4 months of treatment, nicotine significantly reduced the BV/TV (24.5 ± 1.13, 30.8 
± 2.00, 31.3 ± 0.98 %, P < 0.05, respectively) and Ob.S/BS (43.5 ± 2.57, 56.3 ± 2.19, 57.7 ± 1.71 
%, P < 0.0005, respectively), while caused an increased in the Oc.S/BS (25.2 ± 2.58, 15.9 ± 2.10, 
18.5 ± 4.7 %, P < 0.005, respectively) and ES/BS (34.2 ± 0.60 , 23.0 ± 1.61 , 20.7 ± 0.27 %,  P < 
0.0005, respectively) compared with the baseline and control groups (Figures  and 5).  
Nicotine treatment for 4 months caused a significant reduction in the Tb.N (5.5 ± 0.18, 
6.7 ± 0.44, 6.0 ± 0.23 mm-1, P < 0.05, respectively) and an increase in the Tb.Sp (142.0 ± 5.72, 
113.4 ± 10.05 μm, P < 0.05, respectively) compared to the baseline group.  Nicotine treatment 
also decreased the Tb.Th (44.0 ± 1.45, 52.2 ± 1.40 μm, P < 0.05, respectively) as compared to the 
control group (Figures 2 and 5).  There were no significant differences in the OS/BS and the OV/
BV among all 3 groups (Figure 5).  In addition, the control group showed no significant changes in 
all 9 bone histomorphometric parameters as compared to the baseline group (Figures.  and 5).       
Biochemical markers of bone remodeling
Serum cotinine levels were significantly increased after 4 months treatment with nicotine 
as compared to pretreatment (3.2 ± 0.18, 56.1 ± 0.38 ng/ml, P < 0.05, respectively).  However, no 
significant changes were observed in the control group between pretreatment and after 4 months 
treatment with normal saline. After 4 months of treatment, serum cotinine levels in the nicotine 
group were significantly higher than in the control group that was given normal saline  (3.5 ± 0.29, 
56.1 ± 0.38 ng/ml, P < 0.05, respectively) (Figure 6).    
After 4 months of treatment with nicotine, there was a significant decrease in serum 
osteocalcin levels compared to pretreatment values (134.1 ± 9.75, 220.9 ± 34.71 ng/ml, P < 0.05, 
respectively).  However, no significant changes were observed in osteocalcin levels for the control 
group between pretreatment and after 4 months treatment with normal saline.  No significant 
differences were seen between the two groups (Figure 7).  
In both control and nicotine groups, serum pyridinoline levels were increased after 4 months 
treatments as compared to pretreatment (3.7 ± 0.38, 2.5 ± 0.24; 5.2 ± 0.23, 2.0 ± 0.31 nmol/l, P < 
0.005, respectively).  After 4 months treatment, the serum PYD levels were significantly higher 
in the nicotine group as compared to control group (5.2 ± 0.23, 3.7 ± 0.38 nmol/l, P < 0.05, 
respectively) (Figure 8).    
DISCUSSION
The effectiveness of nicotine (7 mg/kg/day) administration in this present study via 
intraperitoneal injection was confirmed by high levels of serum cotinine.  The nicotine group had a 
significantly higher concentration of cotinine after 4 months compared the pretreatment levels and 
to the control group.  The rats which were given nicotine had peak serum cotinine levels ranging 
from 3.3 ng/ml to 56.08 ng/ml, which was almost similar to the concentration of serum cotinine 
seen in humans who smoke between 0 to 0 cigarettes a day (6.59 ng/ml) using ELISA method 
(Ziegler et al., 004).  Another study showed that active smokers usually have serum cotinine levels 
higher than 15 ng/ml (Rebagliato, 2002).  Therefore, the 7 mg/kg body weight nicotine treatment 
used in this study is similar to the degree of smoke exposure experienced by humans who smoke 
moderately.  In addition, the nicotine dose (7mg/kg) chosen in this study was the optimum dose 
to observe on bone based on our previous studies.  Treatment with nicotine 7 mg/kg body weight 
was found to increase bone resorption by induction of the bone-resorbing cytokine, interleukin- 
(Norazlina et al., 004) and also reduced calcium content in left femur as compared to 3mg/kg and 
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Figure 3. Decalcified section (400x magnification) showing the bone cells; osteoblasts (Ob) and osteoclast (Oc) 
which lying on the trabecular bone surface.  Osteoblasts lay down on the organic components of bone matrix; before 
mineralization occurs, the organic matrix is known as osteoid.  Osteoblasts have abundant basophilic cytoplasm, a 
large Golgi apparatus and a pale stained nucleus with a prominent nucleolus, they entrapped in the bone and become 
osteocytes.  Multinucleated osteoclast is shown adjacent to the bone tissue which being resorbed or called as Howship’s 
lacunae (H).  The aspect of the osteoclast in apposition to the bone is characterized by fine microvilli which form a 
ruffled border.  Hematoxylin & Eosin stain.
Figure 4. Osteoid clearly demonstrated in undecalccified section which appears as red stained zone between a layer of 
active osteoblasts (Ob) and the mineralized zone (400 x magnification).    Masson Goldner stain.
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Figure 5. Mean of bone histomorphometric parameters in baseline, control, and nicotine groups.
All values are expressed as mean ± SEM
Baseline group
Control group : Normal saline 0. ml/00g + Olive oil 0. ml/00g
Nicotine group : Nicotine 7mg/kg + Olive oil 0. ml/00kg
* p < 0.05 when compared with baseline group
э p < 0.05 when compared with control group
BV/TV : Trabecular bone volume
Tb.Th : Trabecular thickness
Tb.N : Trabecular number
Tb.Sp : Trabecular separation
Ob.S/BS : Osteoblast surface
Oc.S/BS : Osteoclast surface
ES/BS : Eroded surface
OV/BV : Osteoid volume
OS/BS : Osteoid surface
Figure 6. Mean of serum cotinine level before and after treatment in control group and nicotine group.
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Figure 7. Mean of serum osteocalcin level before and after treatment in control group and nicotine group.
Figure 8. Mean of serum pyridinoline (PYD) level before and after treatment in control group and nicotine group.
Keys to Figures 6-8 :
Control group : Normal saline 0. ml/00g + Olive oil 0. ml/00g
Nicotine group : Nicotine 7mg/kg + Olive oil 0. ml/00kg
All values are expressed as mean ± SEM
* p < 0.05 compared with pretreatment in similar treatment group 
a p < 0.05 compared with after 4 months treatment in control group
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5mg/kg body weight (Ima-Nirwana et al., 006).
 Results of structural bone histomorphometric analysis revealed that nicotine exerted 
negative effects on structural trabecular bone parameters by significantly reducing the BV/TV by 
20% and the Tb.N by 17%, and increasing the Tb.Sp by 25% as compared to the baseline group. 
The nicotine group also had a 22% lower BV/TV, and a 21% higher Tb.Sp than the control group. 
The results of the cellular parameters were consistent with the structural parameters whereby 
nicotine administration significantly caused a reduction in the Ob.S/BS, and an increase in the 
Oc.S/BS and ES/BS as compared to both BC and C groups, respectively.  The Oc.S/BS and Ob.S/
BS are reliable histomorphometric indicator of osteoblast and osteoclast numbers (Parfitt et al., 
1987).  These finding suggest that nicotine caused an increase in bone resorption.     
The changes in trabecular bone structure and cellular bone contents in the nicotine group 
may be due to imbalance in the normal remodeling process.  When rats were exposed nicotine, 
oxidative stress occur which resulted in increased free radical production (Wetscher et al., 995), 
and decreased antioxidant levels and antioxidants enzymes (Kalpana & Menon 004).  Nicotine 
induced osteoclast differentiation by activating NF-kB pathway (Crowley-Weber 003, Jimi & 
Ghosh 005).  Nicotine was also shown to stimulate bone resorption (Henemyre et al., 003). 
Osteoclasts are activated by free radicals (Garrette et al., 990) and osteoclast itself can also produce 
free radicals to resorb bone (Key et al., 990).  This will lead to the formation of many resorption 
pits or eroded bone surfaces.  Decreased osteoblasts number and activity also occurred, which 
may be due to suppression of osteogenesis and osteoblast function (Tanaka et al., 005).  Thus 
the rate of bone formation is insufficient to keep up with resorption.  Excessive bone resorption 
can cause deterioration in trabecular bone microarchitecture leading to bone loss.  Our findings 
suggest that the changes in trabecular bone structure in the nicotine group may due to excessive 
osteoclastogenesis and inadequate osteoblastogenesis. 
In this study, the OS/BS and OV/BV were not significantly different in the nicotine-treated 
group as compared to baseline and control groups.  Based on these results, nicotine treatment 
appeared not to affect the mineralization of the osteoid matrix.  Osteoid is the unmineralized 
organic matrix secreted by osteoblasts and is present in small quantities in normal conditions, 
and is usually regarded as representing an initial stage in the formation of calcified bone tissue 
(Raina 1972).  Previous human and animal studies demonstrated that osteoid can be found in 
osteoporotic and normal bone as well as in osteomalacia (Matsushima et al., 00, Matsushima 
et al., 003; Iwaniec et al., 00).  However, the osteoid volume and the osteoid surface were 
markedly increased in osteomalacia than in normal and osteoporotic bone (Malcom 00).  Thus 
nicotine appears to cause osteoporosis rather than osteomalacia in the rat bone.   
No significant differences were found in all structural and cellular bone histomorphometric 
parameters between baseline and control groups.  These results were consistent with Wronski 
and coworkers (989) who showed that bone histomorphometric parameters were expected 
to be constant between seven and ten months of age in untreated rats, and only decreased to 
approximately 10% by 540 days (21 months of age).  Therefore, many authors (Fung et al., 998, 
999, Iwaniec et al., 000, 00, 00) did not include the baseline control group in their bone 
histomorphometric studies.  
Although many studies found that nicotine caused adverse effects on bone (Riesenfeld 
1985; Ramp et al., 99; Braulik & Jarab, 993; Henemyre et al., 003; Norazlina et al., 004; 
Tanaka et al., 005), but several authors showed that nicotine did not cause any adverse effects on 
bone density, bone strength, bone turnover or cancellous bone histomorphometry on female rats 
(Syversen et al., 999; Fung et al., 998, 999; Iwaniec et al., 000, 00, 00; Akhter et al., 
003).  This may be due to differences in species, gender, dosage, treatment period and method of 
nicotine administration.  An in vivo study by Riesenfeld (1985), reported that female rats tolerated 
nicotine better than male rats and human study also found that self-administration of nicotine per 
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se may be less robust in women and women are less sensitive than male to some effects of nicotine 
(Perkins et al., 999).  Therefore, it may be better to use a male model rather than a female rat 
model to study effects of nicotine on bone.
Bone formation activity, as measured by serum osteocalcin levels, was significantly 
decreased by 39% after 4 months treatment with nicotine as compared to pretreatment.  This result 
is similar to the bone histomorphometric analysis which showed a marked reduction in the Ob.S/
BS after nicotine treatment.  Consistent with this study, earlier research done by de Vernejoul and 
colleagues (983) found that smoking caused a detrimental effect on bone formation by impairment 
of osteoblast activity.  Recently, Liu and coworkers (2001; 2003) reported that cigarette smoke may 
affect bone progenitor cells directly and can interfere with the ability of bone cells to participate in 
repair and remodeling events.  The sequential expression of type I collagen, alkaline phosphatase, 
osteocalcin and deposition of calcium are known as markers of osteoblastic differentiation (Yuhara 
et al., 999) and nicotine administration had also been reported to inhibit collagen synthesis and 
alkaline phosphatase activity in osteoblast-like cells (Ramp et al., 99).  Thus we suggest that 
reduction in osteoblast number and activity in the present study was responsible for the decreased 
production of osteocalcin.  
Bone resorption activity as measured by serum pyridinolline (PYD) levels, was significantly 
increased after 4 months treatment as compared to pretreatment in both the control and nicotine 
groups.  The increase in PYD levels in the control group was expected owing to the increase in 
bone turnover as the rat matures.  In the nicotine group, nicotine treatment caused a 39% higher 
bone turnover rate (higher PYD levels) as compared to control group after 4 months treatment (5. 
± 0.23; 3.7 ± 0.38, P = 0.007).  
PYD and DPD are the collagen cross-links present in bone and also in nonskeletal tissues 
such as cartilage, aorta, tendons and ligaments.  Urinary excretion of these collagen cross-links 
have been shown to be closely related to the bone resorption process (Fujimoto et al., 983).  In 
the case of bone resorption, markers have generally been measured in the urine but this assay have 
some limitations. Their clinical application is hampered by pronounced analytical and biological 
variability, and the need for concurrent measurement of urinary creatinine excretion (Allen 003). 
In addition, it was reported that PYD is not metabolized or absorbed from the diet (Colwell et al., 
993) and assay of serum PYD is a potential marker for bone resorption (Hatta et al., 995).  Since 
measurements in serum circumvent some of the limitations of urinary measurement and reflect 
bone resorption to the same extent as urinary indices (Woitge et al., 999), their use potentially 
improves the assessment of skeletal disorder.  Thus serum PYD was used in this study as a bone 
resorption marker.  
Body weight did not differ and almost at the same rate between control and nicotine group 
at the initiation stage of the study (week-0 to week-6).  This situation showed that the rats were 
healthy and growing normally.  However, in the middle phase of the study starting week-7 until 
the end of the study, nicotine-treated rats weighed between 6.7% (week-7) and 9.6% (week-
6) lower than control rats.  Earlier study by Grunberg and friends (986) showed that nicotine 
administration decreased normal body weight gains in female rats.  In contrast to the present 
study, the gender difference may be one of the reasons why no reduction in body weight was seen. 
Females were found to be more sensitive to the effects of nicotine on body weight as compared 
to the males (Grunberg et al., 986, 987) and female sex hormones may be the reason for this. 
Faraday and coworkers (005) stated that it is possible for estrus cycling to affect female responses 
to nicotine and stress by modifying feeding and corticosterone responses.  In the current study, 
nicotine administration for 4 months did not affect the body weight gain of the rats but it seem to 
be significantly slower as compared to the control group.  More significant differences might be 
seen if the treatment period is prolonged. 
In conclusion, treatment with nicotine 7 mg/kg for 4 months was found to negatively affect 
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both bone histomorphometric and serum biochemical markers of bone remodeling.  This is shown 
by deterioration in trabecular bone structure, increase in osteoclast number and bone resorption 
marker, and decrease in osteoblast number and bone formation marker.   These effects may be due 
to increased oxidative stress induced by nicotine on bone. 
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